罗沙司他在中国血液透析患者中的疗效与安全性：一项系统评价和Meta分析

Efficacy and Safety of Roxadustat in Chinese Hemodialysis Patients: A Systematic Review and Meta-Analysis.

作者信息

Liang Qichen, Li Xu, Niu Qingyu, Zhao Huiping, Zuo Li

机构信息

Department of Nephrology, Peking University People' s Hospital, Beijing 100044, China.

出版信息

J Clin Med. 2023 Mar 23;12(7):2450. doi: 10.3390/jcm12072450.

(1) Background: Recently more and more Chinese clinical studies have been conducted to compare the efficacy and safety of roxadustat with erythropoiesis-stimulating agents (ESAs) in hemodialysis (HD) patients. We aimed to assess the efficacy and safety of roxadustat in Chinese HD patients. (2) Methods: The PubMed, Embase, the Cochrane Library, Web of Science, WanFang, China National Knowledge Infrastructure (CNKI), SinoMed, and VIP databases were searched from their inception to July 2022 for randomized controlled trials (RCTs) that compared the efficacy and safety of roxadustat to those of ESAs in treating anemia in Chinese HD patients. (3) Results: Twenty-one RCTs involving 1408 patients were enrolled. Our study showed that the improvement of hemoglobin (Hb) levels and iron metabolism were significantly higher in the roxadustat group than in the ESA group. Additionally, the total adverse events risk was significantly lower in the roxadustat group. (4) Conclusions: In this meta-analysis, we found that roxadustat was more effective and safer than ESAs in treating anemia in Chinese HD patients.

(1)背景：最近，越来越多的中国临床研究对罗沙司他与促红细胞生成素（ESAs）在血液透析（HD）患者中的疗效和安全性进行了比较。我们旨在评估罗沙司他在中国HD患者中的疗效和安全性。(2)方法：检索PubMed、Embase、Cochrane图书馆、Web of Science、万方、中国知网（CNKI）、中国生物医学文献数据库（SinoMed）和维普数据库，从建库至2022年7月，查找比较罗沙司他与ESAs治疗中国HD患者贫血疗效和安全性的随机对照试验（RCTs）。(3)结果：纳入了21项涉及1408例患者的RCTs。我们的研究表明，罗沙司他组血红蛋白（Hb）水平和铁代谢的改善显著高于ESA组。此外，罗沙司他组的总不良事件风险显著更低。(4)结论：在这项荟萃分析中，我们发现罗沙司他在治疗中国HD患者贫血方面比ESAs更有效、更安全。